Royal Bank of Canada’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Royal Bank of Canada’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-69	Closed	–	–	8017
2023 Q1	$0	Hold	69	–	–	﹤0.01%	7875
2022 Q4	$0	Sell	69 -1	-1%	-$3	﹤0.01%	8222
2022 Q3	$0	Hold	70	–	–	﹤0.01%	8282
2022 Q2	$0	Buy	70 +1	+1%	+$5	﹤0.01%	8236
2022 Q1	$1K	Hold	69	–	–	﹤0.01%	7684
2021 Q4	$1K	Hold	69	–	–	﹤0.01%	7602
2021 Q3	$1K	Buy	+69	New	+$1.14K	﹤0.01%	7582
2020 Q1	–	Hold	0	–	–	–	7343
2019 Q4	–	Hold	0	–	–	–	7407
2019 Q2	–	Hold	0	–	–	–	7478
2019 Q1	–	Hold	0	–	–	–	7420
2018 Q4	–	Hold	0	–	–	–	7544
2018 Q3	–	Hold	0	–	–	–	7232
2018 Q2	–	Hold	0	–	–	–	7051
2018 Q1	–	Hold	0	–	–	–	7182
2017 Q4	–	Hold	0	–	–	–	7250
2017 Q3	–	Hold	0	–	–	–	6658
2017 Q2	–	Hold	0	–	–	–	6999
2017 Q1	–	Hold	0	–	–	–	6249
2016 Q4	–	Hold	0	–	–	–	6136
2016 Q3	–	Hold	0	–	–	–	6344
2016 Q2	–	Hold	0	–	–	–	6306
2016 Q1	–	Hold	0	–	–	–	6005
2015 Q4	–	Hold	0	–	–	–	6250
2015 Q3	–	Hold	0	–	–	–	5669
2015 Q2	–	Hold	0	–	–	–	5417

Other funds holding NVIV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Royal Bank of Canada's NVIV Position: Q2 2023 in Review

Royal Bank of Canada sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2023, closing a stake of 69 shares.

Royal Bank of Canada first reported a position in NVIV in Q3 2021 and held it in 7 quarters. The position peaked at $1K in Q1 2022. 15 funds tracked by Wall St. Rank hold NVIV as of Q2 2023.

Royal Bank of Canada reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2023 after selling out during the quarter.
Royal Bank of Canada sold 69 InVivo Therapeutics Holdings Corp shares in Q2 2023.
Royal Bank of Canada first reported a position in InVivo Therapeutics Holdings Corp in Q3 2021 and held it in 7 quarters.
Royal Bank of Canada's InVivo Therapeutics Holdings Corp position peaked at $1K in Q1 2022.
15 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2023.

Based on Royal Bank of Canada's 13F filing for Q2 2023, filed 14 Aug 2023.